Sepil

Buenos International Private Limited, a leading pharmaceutical manufacturer in India, proudly announces the launch of Sepil, an innovative and highly effective medicine for the treatment of diabetic wound infections, non-healing ulcers, burns, and various types of infective, traumatic, acute, or chronic wounds. Sepil is also highly effective against venous and arterio-venous ulcers.

Sepil is available in an oil formulation, uniquely designed to combat infections caused by both Gram-positive and Gram-negative organisms. Its efficacy extends to critical priority pathogens listed by the World Health Organization (WHO), including Acinetobacter, Pseudomonas, and MRSA.

Sepil represents a significant advancement in wound care, offering a comprehensive solution for patients and healthcare providers. Its multifaceted benefits ensure enhanced healing, reduced infection risk, and improved patient comfort without the drawbacks associated with conventional treatments. With Sepil, Buenos International Private Limited continues its commitment to innovation and excellence in pharmaceutical care.

What sets Sepil apart is its natural product formulation, which boasts 15 key strengths: